NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

FDA Grants Breakthrough Status to Vision-Saving Drug for Optic Neuritis

Oculis (OCS) receives FDA Breakthrough Therapy Designation for Privosegtor, a promising treatment that could become the first neuroprotective therapy for optic neuritis and related eye conditions.

FDA Grants Breakthrough Status to Vision-Saving Drug for Optic Neuritis
Credit: Oculis
Already have an account? Sign in.
01/06/2026 · 10:49 AM
OCS
/ Don’t stop at just one post.

Related↓

Oculis DIAMOND Trial Results: Vision Goal Not Met, But Retina Improved – Company Shifts Focus
05/29/2026 · 4:17 PM

Oculis DIAMOND Trial Results: Vision Goal Not Met, But Retina Improved – Company Shifts Focus

Oculis eye drops failed main vision goal in DME trials but reduced swelling; no FDA filing, company shifts focus, strong cash until 2029.

/ Subscriber only
/ Read more

Feed↓

Qualcomm to Acquire Modular for ~$4 Billion to Challenge NVIDIA in AI Software
Featured/ 06/24/2026 · 9:13 AM

Qualcomm to Acquire Modular for ~$4 Billion to Challenge NVIDIA in AI Software

The deal strengthens Qualcomm’s push into data centers and challenges NVIDIA’s CUDA dominance.

/ Subscriber only
FuelCell Energy Strikes 380 MW Deal with Fit Energy to Power AI Data Centers
06/24/2026 · 8:46 AM

FuelCell Energy Strikes 380 MW Deal with Fit Energy to Power AI Data Centers

Initial 30 MW deployment starts this year.

/ Subscriber only
Hertz Cuts Second-Quarter Outlook as Vehicle Depreciation Pressures Mount
Featured/ 06/24/2026 · 8:25 AM

Hertz Cuts Second-Quarter Outlook as Vehicle Depreciation Pressures Mount

Hertz warned on second-quarter results citing weaker used-car demand and depreciation pressure. The company also announced a $100M borrowed-share offering.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe